companydirectorylist.com  Global Business Directories and Company Directories
Search Business,Company,Industry :


Country Lists
USA Company Directories
Canada Business Lists
Australia Business Directories
France Company Lists
Italy Company Lists
Spain Company Directories
Switzerland Business Lists
Austria Company Directories
Belgium Business Directories
Hong Kong Company Lists
China Business Lists
Taiwan Company Lists
United Arab Emirates Company Directories


Industry Catalogs
USA Industry Directories












Company Directories & Business Directories

BUCKBOROUGH KEITH

SIMCOE-Canada

Company Name:
Corporate Name:
BUCKBOROUGH KEITH
Company Title:  
Company Description:  
Keywords to Search:  
Company Address: 150 Oak St,SIMCOE,ON,Canada 
ZIP Code:
Postal Code:
N3Y 
Telephone Number: 5194292893 
Fax Number:  
Website:
 
Email:
 
USA SIC Code(Standard Industrial Classification Code):
0 
USA SIC Description:
SNOW REMOVAL EQUIP 
Number of Employees:
 
Sales Amount:
 
Credit History:
Credit Report:
 
Contact Person:
 
Remove my name



copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)









Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Your Subject:
Your Comment or Review:
Security Code:



Previous company profile:
BUDD STORES CO LTD
BUDD STORES COMPANY LTD
BUCKWHEATS
Next company profile:
BUCKBOROUGH TERRY
BUCKBOROUGH WAYNE
BUCK C W GENERAL CONTRACTORS










Company News:
  • FDA approves cemiplimab-rwlc for adjuvant treatment of . . .
    On October 8, 2025, the Food and Drug Administration approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals Inc ) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma
  • LIBTAYO® (cemiplimab-rwlc) in Advanced NSCLC, BCC, CSCC . . .
    Learn about LIBTAYO® (cemiplimab-rwlc) in the treatment of advanced NSCLC, BCC, CSCC, as an adjuvant treatment for high-risk CSCC Review Important Safety Info Full Prescribing Information including Med Guide
  • LIBTAYO® Full Prescribing Information | Regeneron
    LIBTAYO (cemiplimab-rwlc) injection for intravenous use is a sterile, preservative-free, clear to slightly opalescent, colorless to pale yellow solution with a pH of 6
  • DailyMed - LIBTAYO- cemiplimab-rwlc injection
    This Medication Guide has been approved by the U S Food and Drug Administration Revised: October 2025 MEDICATION GUIDE - LIBTAYO® (Lib-TIE-oh) (cemiplimab-rwlc
  • label - Food and Drug Administration
    During the treatment period ranging from 8 to 19 months in 5 clinical studies, the incidence of anti-cemiplimab-rwlc antibodies in LIBTAYO-treated patients was 2% (22 1029)
  • LIBTAYO® (cemiplimab-rwlc) | Official HCP Website
    LIBTAYO® (cemiplimab-rwlc) is a prescription medicine indicated for the treatment of adult patients with advanced NSCLC, CSCC, BCC, and as an adjuvant treatment for high-risk CSCC See Important Safety full Prescribing Information
  • Cemiplimab-rwlc - NCI - National Cancer Institute
    FDA label information for this drug is available at DailyMed Use in Cancer Cemiplimab-rwlc is approved to treat: Basal cell carcinoma (BCC) (a type of skin cancer) It is used in patients whose cancer cannot be removed by surgery or has spread after treatment with hedgehog pathway inhibitor therapy or if hedgehog pathway inhibitor therapy cannot be used Cutaneous squamous cell carcinoma (a
  • Libtayo® (cemiplimab-rwlc) Approved in the U. S. as First and . . .
    TARRYTOWN, N Y , Oct 08, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) today announced that the U S Food and Drug Administration (FDA) has approved the PD-1 inhibitor Libtayo ® (cemiplimab-rwlc) as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation The FDA evaluated Libtayo
  • Regeneron Receives FDA Approval for Libtayo; 68% Risk . . .
    Regeneron (NASDAQ: REGN) announced FDA approval of Libtayo (cemiplimab-rwlc) as the first and only immunotherapy for adjuvant treatment of cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation, approved Oct 8, 2025 Approval was based on Phase 3 C-POST results showing a 68% reduction in risk of disease recurrence or death versus placebo (HR 0 32; 95%
  • LIBTAYO (cemiplimab-rwlc) Label - Food and Drug Administration
    LIBTAYO (cemiplimab-rwlc) injection is a clear to slightly opalescent, colorless to pale yellow solution that may contain trace amounts of translucent to white particles




Business Directories,Company Directories
Business Directories,Company Directories copyright ©2005-2012 
disclaimer